MX2017013473A - Agente inductor de inmunidad. - Google Patents
Agente inductor de inmunidad.Info
- Publication number
- MX2017013473A MX2017013473A MX2017013473A MX2017013473A MX2017013473A MX 2017013473 A MX2017013473 A MX 2017013473A MX 2017013473 A MX2017013473 A MX 2017013473A MX 2017013473 A MX2017013473 A MX 2017013473A MX 2017013473 A MX2017013473 A MX 2017013473A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- amino acid
- acid sequences
- polypeptide
- immunity
- Prior art date
Links
- 230000036039 immunity Effects 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 9
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4234—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4235—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta solicitud proporciona un agente inductor de inmunidad que comprende, como un ingrediente activo, al menos un polipéptido que tiene actividad inductora de inmunidad y seleccionado de (a) los polipéptidos que consisten de las secuencias de aminoácidos representadas por las SEQ ID NO: 8, 4, 6, 10, 12, 2 y 14, y los polipéptidos que consisten de 7 o más aminoácidos consecutivos en las secuencias de aminoácidos, (b) los polipéptidos que tienen una identidad secuencial de 85 % o más con las secuencias de aminoácidos representadas por las SEQ ID NO: 8, 4, 6, 10, 12, 2 y 14, y los polipéptidos que consisten de 7 o más aminoácidos consecutivos en las secuencias de aminoácidos, y (c) los polipéptidos que comprenden los polipéptidos de acuerdo a (a) o (b) como las secuencias parciales, o un vector recombinante que comprende un polinucleótido que codifica para el polipéptido, y capaz de expresar el polipéptido in vivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015093354 | 2015-04-30 | ||
| PCT/JP2016/063436 WO2016175309A1 (ja) | 2015-04-30 | 2016-04-28 | 免疫誘導剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017013473A true MX2017013473A (es) | 2017-12-07 |
| MX390696B MX390696B (es) | 2025-03-21 |
Family
ID=57198443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013473A MX390696B (es) | 2015-04-30 | 2016-04-28 | Agente inductor de inmunidad. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180092967A1 (es) |
| EP (1) | EP3290048B1 (es) |
| JP (1) | JP7160462B2 (es) |
| KR (1) | KR102676438B1 (es) |
| CN (1) | CN107530411B (es) |
| AU (1) | AU2016253740B2 (es) |
| CA (1) | CA2983575A1 (es) |
| ES (1) | ES2832523T3 (es) |
| HU (1) | HUE052947T2 (es) |
| MX (1) | MX390696B (es) |
| PL (1) | PL3290048T3 (es) |
| PT (1) | PT3290048T (es) |
| RU (1) | RU2744843C2 (es) |
| WO (1) | WO2016175309A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| JPH09194502A (ja) * | 1995-11-13 | 1997-07-29 | Seikagaku Kogyo Co Ltd | 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体 |
| JP2000095795A (ja) * | 1998-09-18 | 2000-04-04 | Seikagaku Kogyo Co Ltd | プロテオグリカンのコアタンパク質のポリペプチド及びそれをコードするｄｎａ |
| JP2001187799A (ja) | 1999-12-28 | 2001-07-10 | Yasuki Kojima | アポトーシスを誘導するペプチドおよびその用途 |
| JP2003079374A (ja) * | 2001-09-07 | 2003-03-18 | Seikagaku Kogyo Co Ltd | プロテオグリカンのコアタンパク質のポリペプチド、それをコードするｄｎａおよびそのプロモーターｄｎａ |
| WO2006091861A2 (en) * | 2005-02-25 | 2006-08-31 | Ppd Biomarker Discovery Sciences, Llc | Compositions and methods relating to cns lymphoma |
| DK2837383T3 (en) * | 2008-08-05 | 2017-03-20 | Toray Industries | Immunity Inducing Agent |
| HUE037593T2 (hu) | 2009-09-03 | 2018-09-28 | Toray Industries | Immunitásindukáló |
| CN103547278B (zh) * | 2011-05-19 | 2015-11-25 | 东丽株式会社 | 免疫诱导剂 |
| DK2711017T3 (en) | 2011-05-19 | 2016-11-07 | Toray Industries | Immunity-inducing agent |
| CN111053918A (zh) | 2011-09-05 | 2020-04-24 | 韩美科学株式会社 | 一种包含干扰素α-缀合物的抗癌用药物组合物 |
-
2016
- 2016-04-28 PL PL16786585T patent/PL3290048T3/pl unknown
- 2016-04-28 MX MX2017013473A patent/MX390696B/es unknown
- 2016-04-28 US US15/567,448 patent/US20180092967A1/en not_active Abandoned
- 2016-04-28 JP JP2016539235A patent/JP7160462B2/ja active Active
- 2016-04-28 WO PCT/JP2016/063436 patent/WO2016175309A1/ja not_active Ceased
- 2016-04-28 KR KR1020177029643A patent/KR102676438B1/ko active Active
- 2016-04-28 RU RU2017134664A patent/RU2744843C2/ru active
- 2016-04-28 ES ES16786585T patent/ES2832523T3/es active Active
- 2016-04-28 HU HUE16786585A patent/HUE052947T2/hu unknown
- 2016-04-28 CN CN201680023041.XA patent/CN107530411B/zh active Active
- 2016-04-28 PT PT167865856T patent/PT3290048T/pt unknown
- 2016-04-28 CA CA2983575A patent/CA2983575A1/en active Pending
- 2016-04-28 AU AU2016253740A patent/AU2016253740B2/en active Active
- 2016-04-28 EP EP16786585.6A patent/EP3290048B1/en active Active
-
2020
- 2020-01-17 US US16/746,204 patent/US11478539B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017021957A2 (pt) | 2018-07-10 |
| KR102676438B1 (ko) | 2024-06-19 |
| CN107530411B (zh) | 2021-08-13 |
| PT3290048T (pt) | 2020-11-19 |
| RU2017134664A3 (es) | 2019-12-11 |
| WO2016175309A1 (ja) | 2016-11-03 |
| JP7160462B2 (ja) | 2022-10-25 |
| US20180092967A1 (en) | 2018-04-05 |
| EP3290048A4 (en) | 2018-12-19 |
| JPWO2016175309A1 (ja) | 2018-02-22 |
| ES2832523T3 (es) | 2021-06-10 |
| MX390696B (es) | 2025-03-21 |
| KR20170141670A (ko) | 2017-12-26 |
| RU2744843C2 (ru) | 2021-03-16 |
| CA2983575A1 (en) | 2016-11-03 |
| AU2016253740A1 (en) | 2017-11-02 |
| US11478539B2 (en) | 2022-10-25 |
| PL3290048T3 (pl) | 2021-04-06 |
| EP3290048A1 (en) | 2018-03-07 |
| RU2017134664A (ru) | 2019-04-05 |
| CN107530411A (zh) | 2018-01-02 |
| HUE052947T2 (hu) | 2021-05-28 |
| EP3290048B1 (en) | 2020-09-23 |
| AU2016253740B2 (en) | 2021-10-21 |
| US20200138926A1 (en) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2619322T3 (es) | Agente inductor de inmunidad | |
| CL2018001107A1 (es) | Variantes del factor viii cpg reducido, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasis. | |
| MX383887B (es) | Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich. | |
| AR100942A1 (es) | Composiciones y método para el control glucémico que comprenden albiglutida | |
| CO2017004489A2 (es) | Polipéptidos fgf-21 modificados | |
| ECSP15042898A (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| MX2021009696A (es) | Vectores de genoterapia para el tratamiento de la enfermedad de danon. | |
| ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato | |
| PE20220960A1 (es) | Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros | |
| CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
| AR105766A1 (es) | Polipéptidos que tienen actividad de pululanasa adecuados para usar en licuefacción | |
| MY200841A (en) | Influenza Virus Vaccines and Uses Thereof | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| MX2017000094A (es) | PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS. | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| PL3678673T3 (pl) | Kompozycje i sposoby do ukierunkowanego dostarczania, ekspresji i modulowania kodujących kwasów rybonukleinowych w tkankach | |
| AR102410A1 (es) | Polipéptidos que tienen actividad xilanasa con una tasa de conversión alta de polisacáridos que contienen xilosa | |
| AR102061A1 (es) | Genes de chromobacterium subtsugae | |
| MX2018001298A (es) | Agente inductor de inmunidad. | |
| PH12015502037B1 (en) | Activating adiponectin by casein hydrolysate | |
| BR112013029704A2 (pt) | Agente de indutor de imunidade e uso de um agente indutor de imunidade | |
| BR112013029596B8 (pt) | Composição imunogênica | |
| NZ618125A (en) | Genetic vaccines against hendra virus and nipah virus | |
| MX390696B (es) | Agente inductor de inmunidad. | |
| AR099641A1 (es) | OSTEONECTINA (SPARC) COMO BLANCO TERAPÉUTICO PARA EL TRATAMIENTO Y PREVENCIÓN DEL FALLO HEPÁTICO AGUDO, COMPOSICIÓN FARMACEUTICA, CONSTRUCTO GENÉTICO, ARNsi, AGENTE QUE INHIBE LA EXPRESIÓN, USO |